MolNFT v1 · #100912 · protein
Tailoring small molecules for an allosteric site on procaspase-6
4NBL: “Tailoring small molecules for an allosteric site on procaspase-6”. X-ray diffraction, 2 ligands (2J6, PO4), 3 pockets (best druggability 0.50). MolNFT v1 #100912 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4NBL
- Type
- protein
- Length
- 500 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Caspase-6
- EC
- 3.4.22.59
- UniProt
- P55212
- Ligands
- 2J6, PO4
- Pockets
- 3 · best druggability 0.50
Structure
x-ray diffraction · 2 distinct chains · 28% helix, 25% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Caspase-6 (EC 3.4.22.59) | protein | 258 | 28% helix, 24% strand | P55212 |
| B | Caspase-6 (EC 3.4.22.59) | protein | 242 | 28% helix, 26% strand | P55212 |
Ligands and binding sites
- 2J6 · 5-fluoro-2-({[3-(pyrimidin-2-yl)pyridin-2-yl]amino}methyl)phenol · ligand · chains A, B
- PO4 · Phosphate ion · ion · 6 copies · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 132 | 0.50 | 0.80 | 25 | 2J6 |
| 2 | 77 | 0.33 | 0.75 | 20 | PO4 |
| 3 | 69 | 0.33 | 0.76 | 19 | PO4 |
Interfaces
1 interface between chains.
- A–B · 1636 Ų buried · 22 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P55212
- Elsewhere: RCSB PDB 4NBL · PDBe 4NBL · UniProt P55212
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.